TKT and breast carcinoma: Expression levels of transketolase (TKT)—an antagonist of α-KG—could, for instance, regulate the metabolic switch through HIF-1α and PDH2 via the α-KG-dependent dioxygenase signaling and the transcription of SDH and FH to control breast cancer metastasis (64).